JENBURKT PHARMACEUTICALS
|
|
BOM : 524731     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Upward Pledged Shares : None or < 25% |
Aug 30,2024 |
Price(EOD): ₹ 1,111.45
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 489.04 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
JENBURKT PHARMACEUTICALS | -4.2% | 17.6% | 59.8% |
SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 6% | 62.4% |
CIPLA | 3.9% | 7.3% | 33.9% |
DR REDDYS LABORATORIES | 1.2% | 4.2% | 20.1% |
ZYDUS LIFESCIENCES | 1.8% | -9.5% | 80.1% |
DIVIS LABORATORIES | 3.2% | 3.5% | 37.8% |
FUNDAMENTAL ANALYSIS OF JENBURKT PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF JENBURKT PHARMACEUTICALS
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
17.5
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 28.02 Cr
[Latest Qtr - Jun2024 - Standalone Results ] 3.38
P/B Calculated based on Book Value of Rs 144.94 Cr
[Latest Year - Mar2024 - Standalone Results ] 3.38
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Jun2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
77% 72% 74% |
SHARE PRICE MOMENTUM OF JENBURKT PHARMACEUTICALS
JENBURKT PHARMACEUTICALS vs SENSEX
DEBT OF JENBURKT PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0.02 0.05 0.02 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF JENBURKT PHARMACEUTICALS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF JENBURKT PHARMACEUTICALS
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-16.24% -5.72% -2.95% -5.94% |
11.52% 33.33% 35.4% 38.11% |
QtrlyTrend |
0 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
JENBURKT PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about JENBURKT PHARMACEUTICALS
Is JENBURKT PHARMACEUTICALS good for long term investment?
As on Aug 30,2024, the Fundamentals of JENBURKT PHARMACEUTICALS look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of JENBURKT PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is JENBURKT PHARMACEUTICALS UnderValued or OverValued?
As on Aug 30,2024, JENBURKT PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of JENBURKT PHARMACEUTICALS ?
As on Aug 30,2024, the Intrinsic Value of JENBURKT PHARMACEUTICALS is Rs. 640.60 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 626.74
Fair Value [Median EV / Sales Model] : Rs. 644.45
Fair Value [Median Price / Sales Model] : Rs. 640.60
Estimated Median Fair Value of JENBURKT PHARMACEUTICALS : Rs. 640.60
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.